MCID: DRR001
MIFTS: 55

Diarrhea

Categories: Gastrointestinal diseases, Genetic diseases, Infectious diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Diarrhea

MalaCards integrated aliases for Diarrhea:

Name: Diarrhea 11 28 5 41 14 38 75
Diarrhoea 11 14
Diarrhea of Presumed Infectious Origin 11

Classifications:



External Ids:

Disease Ontology 11 DOID:13250
ICD9CM 34 009.2
MeSH 43 D004403
SNOMED-CT 68 154268000
UMLS 71 C0013369

Summaries for Diarrhea

MedlinePlus: 41 What is diarrhea? Diarrhea is loose, watery stools (bowel movements). You have diarrhea if you have loose stools three or more times in one day. Acute diarrhea is diarrhea that lasts a short time. It is a common problem. It usually lasts about one or two days, but it may last longer. Then it goes away on its own. Diarrhea lasting more than a few days may be a sign of a more serious problem. Chronic diarrhea -- diarrhea that lasts at least four weeks -- can be a symptom of a chronic disease. Chronic diarrhea symptoms may be continual, or they may come and go. What causes diarrhea? The most common causes of diarrhea include: Bacteria from contaminated food or water Viruses such as the flu, norovirus, or rotavirus . Rotavirus is the most common cause of acute diarrhea in children. Parasites, which are tiny organisms found in contaminated food or water Medicines such as antibiotics, cancer drugs, and antacids that contain magnesium Food intolerances and sensitivities, which are problems digesting certain ingredients or foods. An example is lactose intolerance. Diseases that affect the stomach, small intestine, or colon, such as Crohn's disease Problems with how the colon functions, such as irritable bowel syndrome Some people also get diarrhea after stomach surgery, because sometimes the surgeries can cause food to move through your digestive system more quickly. Sometimes no cause can be found. If your diarrhea goes away within a few days, finding the cause is usually not necessary. Who is at risk for diarrhea? People of all ages can get diarrhea. On average, adults In the United States have acute diarrhea once a year. Young children have it an average of twice a year. People who visit developing countries are at risk for traveler's diarrhea. It is caused by consuming contaminated food or water. What other symptoms might I have with diarrhea? Other possible symptoms of diarrhea include: Cramps or pain in the abdomen An urgent need to use the bathroom Loss of bowel control If a virus or bacteria is the cause of your diarrhea, you may also have a fever, chills, and bloody stools. Diarrhea can cause dehydration, which means that your body does not have enough fluid to work properly. Dehydration can be serious, especially for children, older adults, and people with weakened immune systems. When do I need to see a health care provider for diarrhea? Although it is usually not harmful, diarrhea can become dangerous or signal a more serious problem. Contact your health care provider if you have: Signs of dehydration Diarrhea for more than 2 days, if you are an adult. For children, contact the provider if it lasts more than 24 hours. Severe pain in your abdomen or rectum (for adults) A fever of 102 degrees or higher Stools containing blood or pus Stools that are black and tarry If children have diarrhea, parents or caregivers should not hesitate to call a health care provider. Diarrhea can be especially dangerous in newborns and infants. How is the cause of diarrhea diagnosed? To find the cause of diarrhea, your health care provider may: Do a physical exam Ask about any medicines you are taking Test your stool or blood to look for bacteria, parasites, or other signs of disease or infection Ask you to stop eating certain foods to see whether your diarrhea goes away If you have chronic diarrhea, your health care provider may perform other tests to look for signs of disease. What are the treatments for diarrhea? Diarrhea is treated by replacing lost fluids and electrolytes to prevent dehydration. Depending on the cause of the problem, you may need medicines to stop the diarrhea or treat an infection. Adults with diarrhea should drink water, fruit juices, sports drinks, sodas without caffeine, and salty broths. As your symptoms improve, you can eat soft, bland food. Children with diarrhea should be given oral rehydration solutions to replace lost fluids and electrolytes. Can diarrhea be prevented? Two types of diarrhea can be prevented - rotavirus diarrhea and traveler's diarrhea. There are vaccines for rotavirus. They are given to babies in two or three doses. You can help prevent traveler's diarrhea by being careful about what you eat and drink when you are in developing countries: Use only bottled or purified water for drinking, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Diarrhea, also known as diarrhoea, is related to diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies and microvillus inclusion disease. An important gene associated with Diarrhea is WNT2B (Wnt Family Member 2B), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Digestion and absorption. The drugs Ceftriaxone and Iron have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and kidney, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Disease Ontology: 11 A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea.

Wikipedia: 75 Diarrhea, also spelled diarrhoea, is the condition of having at least three loose, liquid, or watery... more...

Related Diseases for Diarrhea

Diseases in the Diarrhea family:

Diarrhea 6 Diarrhea 9
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1693)
# Related Disease Score Top Affiliating Genes
1 diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies 33.2 SPINT2 SLC9A3 GUCY2C
2 microvillus inclusion disease 33.1 STX3 SPINT2 SLC9A3 SLC26A3 SKIC3 SKIC2
3 diarrhea 5, with tufting enteropathy, congenital 33.1 STX3 SPINT2 SLC9A3 SLC26A3 SKIC3 SKIC2
4 diarrhea 4, malabsorptive, congenital 33.1 STX3 SPINT2 SKIC3 NEUROG3 MYO5B
5 diarrhea 1, secretory chloride, congenital 33.1 SLC9A3 SLC26A3
6 dysentery 33.1 SLC9A3 SI MGAM
7 acute diarrhea 33.0 SLC9A3 GUCY2C
8 diarrhea 8, secretory sodium, congenital 33.0 SPINT2 SLC9A3 SLC26A3 NEUROG3 MYO5B GUCY2C
9 secretory diarrhea 32.9 STX3 SPINT2 SLC9A3 SLC26A3 MYO5B GUCY2C
10 osmotic diarrhea 32.8 WNT2B SLC9A3 SLC26A3 MYO5B
11 inflammatory diarrhea 32.6 SLC9A3 SLC26A3
12 congenital diarrhea 32.6 STX3 SPINT2 SLC9A3 SLC51B SLC26A3 SKIC3
13 lactase deficiency, congenital 32.2 SPINT2 SLC26A3 MYO5B MGAM
14 sucrase-isomaltase deficiency, congenital 32.2 SI MGAM
15 trichohepatoenteric syndrome 2 31.9 SKIC3 SKIC2
16 proprotein convertase 1/3 deficiency 31.9 NEUROG3 MYO5B
17 primary biliary cholangitis 31.7 SLC51B FOXP3 EPCAM CD40LG
18 bile acid malabsorption, primary, 2 31.6 SLC51B RASL12
19 bowel dysfunction 31.4 SI MGAM GUCY2C
20 mucopolysaccharidosis iii 31.3 SI SGSH MGAM
21 spermatocele 30.2 SLC9A3 SLC26A3
22 pneumatosis cystoides intestinalis 30.1 SI MGAM
23 diabetic autonomic neuropathy 30.0 SI MGAM
24 sphingolipidosis 29.6 SI SGSH MGAM
25 scheie syndrome 29.6 SI SGSH MGAM
26 trichohepatoenteric syndrome 1 11.7
27 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.6
28 congenital chloride diarrhea 11.6
29 diarrhea 2, with microvillus atrophy, with or without cholestasis 11.5
30 congenital diarrhea 7 with exudative enteropathy 11.5
31 diarrhea 6 11.5
32 diarrhea 11, malabsorptive, congenital 11.5
33 diarrhea 9 11.5
34 chronic diarrhea due to guanylate cyclase 2c overactivity 11.4
35 diarrhea 10, protein-losing enteropathy type 11.4
36 vipoma 11.4
37 hemolytic uremic syndrome, atypical 1 11.4
38 gastroenteritis 11.4
39 cholera 11.3
40 diarrhea 12, with microvillus atrophy 11.3
41 satoyoshi syndrome 11.3
42 diarrhea 7, protein-losing enteropathy type 11.3
43 diarrhea, chronic, with villous atrophy 11.3
44 motility-related diarrhea 11.2
45 irritable bowel syndrome 11.2
46 functional diarrhea 11.2
47 severe immune-mediated enteropathy 11.2
48 glucose/galactose malabsorption 11.2
49 prp systemic amyloidosis 11.2
50 cryptosporidiosis 11.2

Graphical network of the top 20 diseases related to Diarrhea:



Diseases related to Diarrhea

Symptoms & Phenotypes for Diarrhea

GenomeRNAi Phenotypes related to Diarrhea according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CD40LG DGAT1 EPCAM FOXP3 GUCY2C MGAM
2 no effect GR00402-S-2 10.18 CD40LG DGAT1 EPCAM FOXP3 GUCY2C MGAM

MGI Mouse Phenotypes related to Diarrhea:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 CD40LG DGAT1 EPCAM FOXP3 GUCY2C MGAM
2 digestive/alimentary MP:0005381 9.28 DGAT1 EPCAM FOXP3 GUCY2C MYO5B NEUROG3

Drugs & Therapeutics for Diarrhea

Drugs for Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530
2
Iron Approved Phase 4 7439-89-6 29936
3
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Mecobalamin Approved, Investigational Phase 4 13422-55-4
7
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
8
Tocopherol Approved, Investigational Phase 4 1406-66-2
9
Eluxadoline Approved, Investigational Phase 4 864821-90-9 11250029
10
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
11
Fidaxomicin Approved Phase 4 873857-62-6 151383
12
Alosetron Approved, Withdrawn Phase 4 122852-42-0 2099
13
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
14
Ferrous fumarate Approved Phase 4 141-01-5
15
Colestipol Approved Phase 4 26658-42-4 62816
16
Tegaserod Approved, Investigational, Withdrawn Phase 4 145158-71-0 5487301 135409453
17
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Chenodeoxycholic acid Approved Phase 4 474-25-9 10133
21
Azithromycin Approved Phase 4 83905-01-5 447043
22
Lactulose Approved Phase 4 4618-18-2 11333
23
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 155817456
24
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521 16682734
25
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
26
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
27
Bisacodyl Approved Phase 4 603-50-9 2391
28
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
29
Trimebutine Approved Phase 4 39133-31-8 5573
30
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
31
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
32
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
33
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
34
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
35
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
38
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
39
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
40
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
41
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
43
Cadexomer iodine Experimental Phase 4 94820-09-4
44
Cobalamin Experimental Phase 4 13408-78-1 6857388
45
Tocotrienol Investigational Phase 4 6829-55-6 9929901
46
Racecadotril Investigational Phase 4 81110-73-8 107751
47
Ramosetron Investigational Phase 4 132036-88-5 4442 108000
48
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2 91976570
49 Antibiotics, Antitubercular Phase 4
50 Bile Acids and Salts Phase 4

Interventional clinical trials:

(show top 50) (show all 804)
# Name Status NCT ID Phase Drugs
1 Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle Unknown status NCT01469273 Phase 4 Mutaflor® Suspension
2 Bacillus Particles Prevent More Children's Antibiotic-associated Diarrhea (AAD), Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT02993419 Phase 4 Bacillus licheniformis Intervention
3 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
4 Crofelemer for Functional Diarrhea Unknown status NCT04486326 Phase 4 Crofelemer;Placebo
5 The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial Unknown status NCT01792739 Phase 4 Lactobacillus casei variety rhamnosus granules;Placebo
6 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
7 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
8 Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With Diarrhoea-predominant Irritable Bowel syndrome-a Multicentre Controlled Study Unknown status NCT04074421 Phase 4 Rifaximin;Probiotic Formula;Placebo oral tablet
9 The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial Completed NCT01927094 Phase 4
10 A Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack(Comprising of Low Osmolality ORS, Zinc Tablets, Water Purification Tablets and Pictorial Chart) on Childhood Diarrhea. Completed NCT00942812 Phase 4
11 Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Completed NCT02462590 Phase 4 L. rhamnosus GG - Probiotic;Placebo - Microcrystalline Cellulose
12 Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial Completed NCT02871908 Phase 4 Lactobacillus reuteri DSM 17938;Placebo
13 Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety Completed NCT00447161 Phase 4 Bacillus Clausii Multi ATB Resist;Placebo
14 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Completed NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
15 Efficacy and Safety of Saccharomyces Boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Patients Suffering From Irritable Bowel Syndrome With Diarrhea Completed NCT04627337 Phase 4 Saccharomyces Boulardii 250 MG
16 Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome Completed NCT02111603 Phase 4 Colesevelam
17 Postmarketing Study of Probiotics Medication in Childhood Diarrhea Completed NCT00463190 Phase 4 Biothree
18 A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea Completed NCT02607176 Phase 4 Heweizhixie capsule
19 Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study Completed NCT00700557 Phase 4
20 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial Completed NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
21 A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults Completed NCT00807326 Phase 4 Loperamide/simeticone 2 mg/125 mg caplets;Loperamide/simeticone 2 mg/125 mg chewable tablets;Probiotic Saccharomyces boulardii 250 mg capsules
22 A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF) Completed NCT02959983 Phase 4 Eluxadoline;Placebo
23 A Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Appropriateness of Multiple Endpoints in Measuring the Onset of Clinical Efficacy of Loperamide-Simethicone Caplets in the Treatment of Acute Non-specific Diarrhea Completed NCT00685607 Phase 4 loperamide-simethicone;matching placebo
24 Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea : A Pilot, Randomized, Control-case Study Completed NCT03356327 Phase 4 Actitan F;Standard Oral Rehydration
25 A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects Completed NCT00370032 Phase 4 alosetron
26 A Clinical Trial for the Off Label Use of Ursodiol for the Prevention of Recurrent C. Difficile Colitis and Diarrhea Completed NCT02748616 Phase 4 Ursodiol
27 Supplementation With a Multi-strain Probiotic Formulation (Bio-Kult®) in the Management of Diarrhea-predominant Irritable Bowel Syndrome - a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT03251625 Phase 4 Probiotic Formula Capsule
28 STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea Completed NCT00050635 Phase 4 Sandostatin LAR Depot
29 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
30 Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project Completed NCT01088958 Phase 4
31 Saccharomyces Boulardii in the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients With Lower Respiratory Tract Infections Completed NCT05261152 Phase 4 drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
32 A Double-blind, Placebo-controlled Study to Assess the Effect of Probiotic on Symptom Relief and Indices of Micro-inflammation and Cholinergic Status in IBS Patients With Diarrhea. Completed NCT01667627 Phase 4
33 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
34 Double Blinded, Randomized Controlled Trial of Oral Vancomycin Versus Placebo in Hospitalized Patients With Diarrhea and Stool toXin NEGative But Nucleic Acid Amplification Test Positive for Toxigenic Clostridium Difficile (TOX NEG Trial) Completed NCT03388268 Phase 4 Oral Vancomycin;Placebo
35 Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone Completed NCT00359970 Phase 4 Azithromycin 500 mg;Azithromycin 1000 mg;Loperamide
36 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
37 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
38 Effect of Zinc Sulphate and Zinc Amino Acid Chelate in Prevention Acute Diarrhea and Acute Respiratory Infection, Medellín 2012 Completed NCT01791608 Phase 4
39 Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months. Completed NCT01571856 Phase 4 Zinc Sulfate
40 Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children: A Randomized Double-blind Trial Completed NCT01564290 Phase 4 Placebo probiotic
41 Bacillus Clausii in the Treatment of Acute Community-acquired Diarrhea Among Latin American Children (cadiLAc) Completed NCT02169817 Phase 4 Bacillus clausii;Oral Rehydration Therapy
42 Efficacy of Racecadotril in the Management of Acute Watery Diarrhea in Children Completed NCT01577043 Phase 4 Racecadotril
43 3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM) Completed NCT03441581 Phase 4 Eluxadoline
44 The Effect of Daily Zinc Supplementation on Prevention of Diarrhea and Acute Respiratory Infections Among Children Less Than Five Years: A Randomized Controlled Trial Completed NCT05002101 Phase 4 Placebo
45 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Completed NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
46 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
47 An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months) Completed NCT01960725 Phase 4
48 Antibiotic-associated Gastrointestinal Side Effects and the Role of the Gut Microbiome Completed NCT04156555 Phase 4 Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
49 Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in Emergency Departments in Pakistan Completed NCT01870648 Phase 4 Ondansetron;Placebo
50 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4

Search NIH Clinical Center for Diarrhea

Genetic Tests for Diarrhea

Genetic tests related to Diarrhea:

# Genetic test Affiliating Genes
1 Diarrhea 28

Anatomical Context for Diarrhea

Organs/tissues related to Diarrhea:

MalaCards : Colon, Small Intestine, Kidney, Skin, Heart, Breast, Lung

Publications for Diarrhea

Articles related to Diarrhea:

(show top 50) (show all 59035)
# Title Authors PMID Year
1
Pediatric diarrhea and lactose products. 62 41
36376038 2022
2
Diagnostic testing practices for diarrhoeal cases in South African public hospitals. 62 41
36352368 2022
3
The magnitude of oral rehydration salt utilization in diarrhea hot spot regions of Ethiopia and its associated factors among under-five children: A multilevel analysis based on Bayesian approach. 62 41
36438299 2022
4
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
5
A case report of olmesartan-associated sprue-like enteropathy: Diagnosis and healing confirmed by capsule endoscopy. 62
35898826 2023
6
Streptomyces genus as a source of probiotics and its potential for its use in health. 62
36335804 2023
7
Geographical variation in the effect of ambient temperature on infectious diarrhea among children under 5 years. 62
36208789 2023
8
Colchicine increases intestinal toxic load by disturbing fecal metabolome homeostasis in mice. 62
36179773 2022
9
A systematic literature review on the economic impact of endemic disease in UK sheep and cattle using a One Health conceptualisation. 62
36332284 2022
10
Clinical symptoms associated with laboratory findings and placental histopathology in full-term, non-infected neonates born to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive mothers. 62
34762576 2022
11
Transcutaneous Electrical Acustimulation Improved the Quality of Life in Patients With Diarrhea-Irritable Bowel Syndrome. 62
35088760 2022
12
Non-structural proteins of bovine viral diarrhea virus. 62
35614328 2022
13
U-shaped association between sleep duration with chronic constipation and diarrhea: A population-based study. 62
36322395 2022
14
Feasibility of MinION Nanopore Rapid Sequencing in the Detection of Common Diarrhea Pathogens in Fecal Specimen. 62
36413486 2022
15
Comparative analysis of the fecal microbiome and metabolomics of healthy versus captive South China tigers with mild diarrhea. 62
36194899 2022
16
Tong-Xie-Yao-Fang alleviates diarrhea-predominant irritable bowel syndrome in rats via the GCN2/PERK-eIF2α-ATF4 signaling pathway. 62
36194974 2022
17
Clinical status and endoscopy of the upper respiratory tract of dairy calves infected with Bovine viral diarrhea virus 2 and Bovine herpes virus 1 after vaccination and trace minerals injection. 62
36201905 2022
18
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. 62
36280642 2022
19
Undiagnosed Exocrine Pancreatic Insufficiency in Diarrhea-Predominant Irritable Bowel Syndrome. 62
35705731 2022
20
Efficacy of Microencapsulated Probiotic as Adjunct Therapy on Resolution of Diarrhea, Copper-Zinc Homeostasis, Immunoglobulins, and Inflammatory Markers in Serum of Spontaneous Rotavirus-Infected Diarrhoetic Calves. 62
34676503 2022
21
Porcine epidemic diarrhea virus E protein inhibits type I interferon production through endoplasmic reticulum stress response (ERS)-mediated suppression of antiviral proteins translation. 62
36029572 2022
22
[71/f-Recurrent vomiting and diarrhea with continuous weight loss : Preparation for the medical specialist examination: part 5]. 62
36066590 2022
23
Association of bovine viral diarrhea virus, bovine herpesvirus 1, and Neospora caninum with late embryonic losses in highly supplemented grazing dairy cows. 62
36242875 2022
24
Porcine epidemic diarrhea virus 3CLpro causes apoptosis and collapse of mitochondrial membrane potential requiring its protease activity and signaling through MAVS. 62
36335841 2022
25
Alpiniae oxyphyllae fructus polysaccharide 3 inhibits porcine epidemic diarrhea virus entry into IPEC-J2 cells. 62
36126510 2022
26
Investigation of hemogram, oxidative stress, and some inflammatory marker levels in neonatal calves with escherichia coli and coronavirus diarrhea. 62
36191841 2022
27
Occurrence of microsporidia spp. infection in children with diarrhea in southern Iran. 62
36457786 2022
28
Augmentation of 3β-hydroxysteroid-Δ24 Reductase (DHCR24) Expression Induced by Bovine Viral Diarrhea Virus Infection Facilitates Viral Replication via Promoting Cholesterol Synthesis. 62
36468862 2022
29
Characterization and pathogenicity of the porcine epidemic diarrhea virus isolated in China. 62
36473667 2022
30
Impact of international travel and diarrhea on gut microbiome and resistome dynamics. 62
36470885 2022
31
Prevalence and detection of Tropheryma whipplei in the stools of Korean patients with diarrhea using real-time PCRs. 62
36474214 2022
32
A Case of Chronic Diarrhea With Weight Loss. 62
35863530 2022
33
Increase in Serum Calcitonin Gene-Related Peptide β (CGRPβ) Levels in COVID-19 Patients with Diarrhea: An Underlying Mechanism? 62
35305169 2022
34
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile. 62
36382550 2022
35
Cholera Outbreak 2022 in Karachi: A Report on Serotype and Antibiotic Susceptibility Pattern. 62
36474386 2022
36
Differential diagnosis of ulcerative colitis with increased diarrhea; collagenous colitis or irritable bowel syndrome? A case report. 62
36474409 2022
37
A novel SPINT2 missense mutation causes syndromic congenital sodium diarrhea. 62
36123503 2022
38
Examining knowledge and traditional practices of mothers with children under five in Turkey on diarrhoea according to education levels. 62
35225109 2022
39
Women empowerment indicators and uptake of child health services in sub-Saharan Africa: a multilevel analysis using cross-sectional data from 26 countries. 62
34059913 2022
40
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. 62
35973804 2022
41
COVID-19 associated Pancytopenia (CAP): A Clinical Impact. 62
36475340 2022
42
PCR investigation of infections in patients consulting at a healthcare centre over a four-year period during the Grand Magal of Touba. 62
36470351 2022
43
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. 62
36247927 2022
44
Microvillous inclusion disease as a cause of severe congenital diarrhea in a newborn. 62
33843415 2022
45
Identification of key proteins of cytopathic biotype bovine viral diarrhoea virus involved in activating NF-κB pathway in BVDV-induced inflammatory response. 62
36316807 2022
46
Lethal acute diarrhea associated with Clostridioides difficile toxin A and B in a buffy-tufted-ear marmoset (Callithrix aurita). 62
35989431 2022
47
Furin cleavage is required for swine acute diarrhea syndrome coronavirus spike protein-mediated cell - cell fusion. 62
35976165 2022
48
Swine coronaviruses (SCoVs) and their emerging threats to swine population, inter-species transmission, exploring the susceptibility of pigs for SARS-CoV-2 and zoonotic concerns. 62
35584308 2022
49
Sleep duration prior to an enterotoxigenic Escherichia coli challenge predicts diarrhea severity during infection. 62
36240601 2022
50
Genome-Wide CRISPR/Cas9 Screen Reveals a Role for SLC35A1 in the Adsorption of Porcine Deltacoronavirus. 62
36453883 2022

Variations for Diarrhea

ClinVar genetic disease variations for Diarrhea:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 WNT2B NM_024494.3(WNT2B):c.205C>T (p.Arg69Ter) SNV Pathogenic
545432 rs370244148 GRCh37: 1:113057518-113057518
GRCh38: 1:112514896-112514896
2 SGSH NM_000199.5(SGSH):c.1272_1282del (p.Tyr424_Arg428delinsTer) DEL Pathogenic
287037 rs752914124 GRCh37: 17:78184478-78184488
GRCh38: 17:80210679-80210689
3 SGSH NM_000199.5(SGSH):c.892T>C (p.Ser298Pro) SNV Pathogenic
30459 rs138504221 GRCh37: 17:78185927-78185927
GRCh38: 17:80212128-80212128
4 NMNAT1 NM_022787.4(NMNAT1):c.769G>A (p.Glu257Lys) SNV Likely Pathogenic
37134 rs150726175 GRCh37: 1:10042688-10042688
GRCh38: 1:9982630-9982630
5 RASL12, SLC51B NM_178859.4(SLC51B):c.84del (p.Arg29fs) DEL Likely Pathogenic
804474 rs1595900104 GRCh37: 15:65342421-65342421
GRCh38: 15:65050083-65050083
6 OCA2 NM_000275.3(OCA2):c.2020C>G (p.Leu674Val) SNV Uncertain Significance
194918 rs371412500 GRCh37: 15:28171332-28171332
GRCh38: 15:27926186-27926186
7 SHH NM_000193.4(SHH):c.86G>C (p.Gly29Ala) SNV Uncertain Significance
1338810 GRCh37: 7:155604731-155604731
GRCh38: 7:155812037-155812037
8 UNC45A NM_018671.5(UNC45A):c.710T>C (p.Leu237Pro) SNV Uncertain Significance
978046 rs1291676751 GRCh37: 15:91485689-91485689
GRCh38: 15:90942459-90942459
9 UNC45A NM_018671.5(UNC45A):c.1339_1340delinsCT (p.Ala447Leu) INDEL Uncertain Significance
978047 rs2036591621 GRCh37: 15:91489983-91489984
GRCh38: 15:90946753-90946754

Expression for Diarrhea

Search GEO for disease gene expression data for Diarrhea.

Pathways for Diarrhea

GO Terms for Diarrhea

Cellular components related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.4 STX3 SLC9A3 SLC26A3 SI MGAM EPCAM
2 Ski complex GO:0055087 9.26 SKIC3 SKIC2

Biological processes related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immunoglobulin production GO:0002637 8.8 FOXP3 CD40LG

Molecular functions related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alpha-glucosidase activity GO:0090599 8.96 SI MGAM
2 alpha-1,4-glucosidase activity GO:0004558 8.92 SI MGAM

Sources for Diarrhea

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....